How a demoted researcher’s persistence built the foundation for modern mRNA vaccine technology.
In short: Katalin Karikó spent decades pursuing mRNA research despite institutional skepticism, funding cuts, and professional demotion. Her refusal to abandon a field others deemed unpromising eventually led to the nucleoside modifications that made mRNA therapeutics viable, ultimately enabling the rapid development of life-saving COVID-19 vaccines and earning her a Nobel Prize.
Born in 1955 in Szolnok, Hungary, Katalin Karikó’s early life was marked by modest means and a rigorous academic focus. After earning her PhD in biochemistry in 1982, she moved to the United States in 1985 to continue her research. Her path was far from smooth; she faced significant professional hurdles, including a demotion at the University of Pennsylvania in 1995 after years of grant rejections and a lack of institutional support for her focus on mRNA-based gene therapy.
The breakthrough came through her collaboration with immunologist Drew Weissman, whom she met at the University of Pennsylvania in 1997. Together, they tackled the major obstacle that had stalled mRNA research: the molecule’s tendency to trigger severe inflammatory immune responses when introduced into the body. By comparing synthetic mRNA to transfer RNA, they discovered that replacing uridine with pseudouridine rendered the mRNA non-immunogenic. This discovery, though initially rejected by major journals like Nature and Science, was eventually published in Immunity and provided the essential mechanism for therapeutic use.
Beyond chemical modification, Karikó and Weissman developed a delivery system using lipid nanoparticles—tiny fat droplets that protect the fragile mRNA until it reaches its target. This combined technology was licensed by companies like BioNTech and Moderna. The success of these vaccines during the COVID-19 pandemic brought global recognition to Karikó’s decades of work. She has since received over 130 international honors, including the 2023 Nobel Prize in Physiology or Medicine, and continues to advocate for the potential of mRNA in treating cancer, cardiovascular, and metabolic diseases.
Karikó’s career serves as a testament to the power of scientific persistence. Despite being discouraged by her university and facing skepticism from the broader scientific community, she remained committed to her vision. Today, her work is recognized not just for its role in the pandemic, but as the foundation for an entirely new class of drugs that could transform medicine.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Katalin Karikó
To cite this card, link to https://intellectplus.co.uk/app/technology-katalin-karik.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Vaccines · More in Health · Latest · A–Z · All topics